We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist
Read MoreHide Full Article
On Dec 29, 2016, we issued an updated research report on Parsippany, NJ-based Zoetis Inc. (ZTS - Free Report) .
Zoetis is one of the leading global animal health companies focused on both livestock and companion animals. Shares of the company have outperformed the Zacks classified Medical - Drugs industry, year to date. In fact, the stock has gained 12.8% during this period, as against a decline of 25.1% for the industry.
The company’s companion animal business has been performing well, driven by higher sales of Apoquel, new product launches including Simparica and recent additions to the vaccine portfolio. Zoetis projects the companion animal business to be the main growth driver in 2017. Meanwhile, it expects to see growth in the livestock business as it overcomes product rationalization impacts.
Zoetis has been working on strengthening its product portfolio through acquisitions and deals. In Aug 2016, it acquired a veterinary diagnostic focused company, Scandinavian Micro Biodevices, for $80 million. The acquisition should expand Zoetis’ offerings in the growing veterinary diagnostics segment of the animal health market. Thus, we expect to see more of such acquisitions/deals at Zoetis as it continues to focus on the strategy of acquiring complementary businesses and products.
Meanwhile, it is focused on gross margin expansion and cost control. The company’s comprehensive operational efficiency initiatives are expected to enerate cost savings of over $300 million by 2017 end.
The company is also working on returning value to shareholders in the form of share buybacks and dividends.
The company has consistently surpassed expectations in the four trailing quarters along with regular increases in guidance. At the time of announcing third-quarter 2016 results, Zoetis raised the earnings outlook for 2016 yet again, buoyed by a strong performance through the first nine months of the year, and continued strength in the company’s business model.
Zoetis expects earnings in the range of $1.91 to $1.96 per share (old guidance: $1.86–$1.93). It also raised the lower end of its revenue guidance for 2016 to the range of $4.85 billion to $4.9 billion (old guidance: $4.8–$4.9 billion).
Zoetis also upped the lower end of both its earnings and revenue guidance for 2017. The company expects earnings in the range of $2.28 to $2.38 per share (old guidance: $2.24–$2.38) on revenues of $5.15 billion to $5.275 billion (old guidance: $5.075–$5.275 billion).
The increased outlook is seen as achievable on the back of a diversified product portfolio, streamlined infrastructure and prudent acquisitions.
The Zacks Rank #3 (Hold) stock has seen its earnings per share estimates for 2016 increase 3.2% to $1.95 and 0.4% to $2.35 for 2017, over the last 60 days. The company’s expected growth rate is 10.2% and 20.5% for 2016 and 2017, respectively.
Despite the abovementioned positives, Zoetis has its own share of problems. While the performance of the livestock business is concerning, headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.
Stocks to Consider
Some better-ranked stocks in this industry include Nivalis Therapeutics, Inc. , Sucampo Pharmaceuticals, Inc. and Akebia Therapeutics, Inc. (AKBA - Free Report) . While Nivalis and Sucampo are Zacks Rank #1 (Strong Buy) stocks, Akebia carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Nivalis’ loss estimates narrowed from $2.29 to $2.08 for 2016 and from $2.64 to $1.81 for 2017, over the last 60 days.
Akebia’s loss estimates narrowed from $4.07 to $0.39 for 2016 and from $3.73 to $1.13 for 2017, over the last 60 days.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.74 for 2017, over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 35.55%.
Now See Our Private Investment Ideas
While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist
On Dec 29, 2016, we issued an updated research report on Parsippany, NJ-based Zoetis Inc. (ZTS - Free Report) .
Zoetis is one of the leading global animal health companies focused on both livestock and companion animals. Shares of the company have outperformed the Zacks classified Medical - Drugs industry, year to date. In fact, the stock has gained 12.8% during this period, as against a decline of 25.1% for the industry.
The company’s companion animal business has been performing well, driven by higher sales of Apoquel, new product launches including Simparica and recent additions to the vaccine portfolio. Zoetis projects the companion animal business to be the main growth driver in 2017. Meanwhile, it expects to see growth in the livestock business as it overcomes product rationalization impacts.
Zoetis has been working on strengthening its product portfolio through acquisitions and deals. In Aug 2016, it acquired a veterinary diagnostic focused company, Scandinavian Micro Biodevices, for $80 million. The acquisition should expand Zoetis’ offerings in the growing veterinary diagnostics segment of the animal health market. Thus, we expect to see more of such acquisitions/deals at Zoetis as it continues to focus on the strategy of acquiring complementary businesses and products.
Meanwhile, it is focused on gross margin expansion and cost control. The company’s comprehensive operational efficiency initiatives are expected to enerate cost savings of over $300 million by 2017 end.
The company is also working on returning value to shareholders in the form of share buybacks and dividends.
The company has consistently surpassed expectations in the four trailing quarters along with regular increases in guidance. At the time of announcing third-quarter 2016 results, Zoetis raised the earnings outlook for 2016 yet again, buoyed by a strong performance through the first nine months of the year, and continued strength in the company’s business model.
Zoetis expects earnings in the range of $1.91 to $1.96 per share (old guidance: $1.86–$1.93). It also raised the lower end of its revenue guidance for 2016 to the range of $4.85 billion to $4.9 billion (old guidance: $4.8–$4.9 billion).
Zoetis also upped the lower end of both its earnings and revenue guidance for 2017. The company expects earnings in the range of $2.28 to $2.38 per share (old guidance: $2.24–$2.38) on revenues of $5.15 billion to $5.275 billion (old guidance: $5.075–$5.275 billion).
The increased outlook is seen as achievable on the back of a diversified product portfolio, streamlined infrastructure and prudent acquisitions.
The Zacks Rank #3 (Hold) stock has seen its earnings per share estimates for 2016 increase 3.2% to $1.95 and 0.4% to $2.35 for 2017, over the last 60 days. The company’s expected growth rate is 10.2% and 20.5% for 2016 and 2017, respectively.
ZOETIS INC Price and Consensus
ZOETIS INC Price and Consensus | ZOETIS INC Quote
Despite the abovementioned positives, Zoetis has its own share of problems. While the performance of the livestock business is concerning, headwinds remain in the form of disease outbreaks and stiff competition in the animal health space.
Stocks to Consider
Some better-ranked stocks in this industry include Nivalis Therapeutics, Inc. , Sucampo Pharmaceuticals, Inc. and Akebia Therapeutics, Inc. (AKBA - Free Report) . While Nivalis and Sucampo are Zacks Rank #1 (Strong Buy) stocks, Akebia carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Nivalis’ loss estimates narrowed from $2.29 to $2.08 for 2016 and from $2.64 to $1.81 for 2017, over the last 60 days.
Akebia’s loss estimates narrowed from $4.07 to $0.39 for 2016 and from $3.73 to $1.13 for 2017, over the last 60 days.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.74 for 2017, over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 35.55%.
Now See Our Private Investment Ideas
While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>